secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001601830-23-000022
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion acquires Cyclica ($40M) & Valence ($47.5M); Q1 net loss $65.3M
------------------------------------------------------------------------

- Entered agreements to acquire Cyclica for $40M and Valence for $47.5M, payable in stock; expected Q2 2023 close.
- Q1 cash $473.1M; revenue $12.1M (up from $5.3M YoY) driven by Roche-Genentech collaboration.
- Net loss $65.3M vs $56.0M Q1 2022; R&D expenses rose to $46.7M on platform expansion.
- Phase 2 SYCAMORE trial (REC-994) in CCM: >80% enrolled; top-line data expected H2 2024.
- Phase 2/3 POPLAR trial (REC-2282) in NF2-mutated meningiomas; interim safety analysis expected 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183023000022/0001601830-23-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183023000022/rxrx-20230508.htm
  HTML page:      https://secwatch.observer/filing/0001601830-23-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer